87488-61-7

Upstream product

• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 67-63-0 isopropyl alcohol 
• 614-21-1 2-nitroacetophenone 
• 577-59-3 2-acetylnitrobenzene 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 305811-50-1 1-(2,2,2-trifluoroethyl)-5-(2-nitrophenyl)pyrazole 
• 1126078-22-5 4-(2-nitrophenyl)pyrimidin-2-ylamine 
• 87488-62-8 5-(2-nitrophenyl)isoxazole 
• 111562-32-4 2-(1H-pyrazol-3-yl)aniline 
• 59844-05-2 3-(2-nitrophenyl)-1H-pyrazole 
• 681827-50-9 benzyl 2-methyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate 
• 83-54-5 1-methyl-4-quinolone 
• 172538-83-9 benzyl 4-oxoquinoline-1(4H)-carboxylate 
• 35928-59-7 2,2-dibromo-1-(2-nitrophenyl)ethan-1-one 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.

FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compound-linker constructs and antibody-drug-conjugates of compounds of formula (I) that are useful as modulators of STING (Stimulator of Interferon Genes).

Conjugate Addition Routes to 2-Alkyl-2,3-dihydroquinolin-4(1H)-ones and 2-Alkyl-4-hydroxy-1,2-dihydroquinoline-3-carboxylates

Under CuBr·SMe2/PPh3 catalysis (5/10 mol-%) RMgCl (R = Me, Et, nPr, CH=CH2, nBu, iBu, nC5H11, cC6H11, Bn, CH2Bn, nC11H23) readily (–78 °C) undergo 1,4-addition to Cbz or Boc protected quinolin-4(1H)-ones to provide 2-alkyl-2,3-dihydroquinolin-4(1H)-ones (14 examples, 54–99 % yield). Asymmetric versions require AlEt3 to Boc-protected ethyl 6-substituted 4(1H)-quinolone-3-carboxylates (6-R group = all halogens, n/i/t-alkyls, CF3) and provide 61–91 % yield, 30–86 % ee; any halogen, Me, or CF3 provide the highest stereoselectivities (76–86 % ee). Additions of AlMe3 or Al(nC8H17)3 provide ≈ 45 and ≈ 75 % ee on addition to the parent (6-R = H). Ligand (S)-(BINOL)P–N(CHPh2)(cC6H11) provides the highest ee values engendering addition to the Si face of the 4(1H)-quinolone-3-carboxylate. Allylation and deprotection of a representative 1,4-addition product example confirm the facial selectivity (X-ray crystallography).

Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation

A series of novel 2,4-diarylaminopyrimidine derivatives of AZD9291 were discovered as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors. The majority of these compounds exhibited moderate to excellent EGFR T790 M/L858R inhibitory activities and comparable anti-proliferative activities against double mutant over-expressed NCI-H1975 cells to that of AZD9291. The most promising compounds 8a displayed an IC50 of 4.1 nM against EGFR L858R/T790M mutants. 8a also showed excellent cytotoxic effect against NCI-H1975 cells with an IC50 of 59 nM and 100-fold selectivity over wide-type EGFR over-expressed A431 cells. Compound 8a significantly inhibited tumor growth in NCI-H1975 xenograft models at a non-toxic dose. Docking study performed for 8a with ATP binding site of EGFR-TK showed the similar binding mode to that of AZD9291. All these results suggested that compound 8a was a potential mutant-selective EGFR inhibitor.

Pyrimidine compounds

The present invention belongs to the field of pharmaceutical synthesis, and relates to pyrimidine compounds, a preparation method and applications thereof, a pharmaceutical composition containing the pyrimidine compounds as active components, and applications of the pyrimidine compounds in preparation of antitumor drugs. The present invention discloses a pyrimidine compound having a structure represented by a formula I, wherein W is NH, R1 is a nitrogen-containing five-membered heterocyclic ring, and R2 is a nitrogen-containing basic group. According to the present invention, the pyrimidine compound can inhibit a variety of tumor cells, can particularly and selectively act on EGFRL858R/T790M lung cancer cells, and can overcome the existing EGFR inhibitors, wherein the IC50 of the compounds is increased by 10-100 times compared to wild-type cells. The formula I is defined in the specification.

PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF

The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR

The invention relates to compounds of the formula (I) and their use as pharmaceutical ingredients, in particular for the treatment of CNS related diseases.

Easily attachable and detachable ortho-directing agent for arylboronic acids in ruthenium-catalyzed aromatic C-H silylation

(Chemical Equation Presented) o-C?H silylation of arylboronic acids has been achieved using 2-pyrazol-5-ylaniline as an orthodirecting agent, which was temporarily attached to the boronyl group via Ru-catalyzed silylation with hydrosilanes. Condensation products of arylboronic acids with2-pyrazol-5-ylaniline were prepared in situ and subjected to reaction w ith triorganosilanes in the presence of RuH2(CO)(PPh3) 3 at 135°C. Regioselective silylation at their ortho-positions proceeded in good yields for phenylboronic acids bearing para-substituents such as chloro, fluoro, methyl, methoxy, and trifluoromethyl groups. p-Methoxycarbonyl-substituted phenylboronic acid provided thecorresponding silylated product in moderate yield. m-Tolyl- and 2-napht hylboronic acids underwent silylation selectively at the less stericallyhindered ortho-positions. The silylated products were utilized in Suzuk i?Miyaura coupling, followed either by iodination with ICl or by Tamao oxidation to furnish iodine- or hydroxy-substituted biaryls.

3-AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The present invention relates to 3-azabicyclo[3.1.0]hexane derivatives, which are useful as vanilloid receptor (VR) ligands, methods of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.

Novel and convenient synthesis of 4(1H)quinolones

A rapid two-step synthesis of 4(1H)quinolones is described. The first step involves condensation of o-nitroacetophenone with N,N-dimethylformamide dimethylacetal yielding highly crystalline enamines. In the second step a reductive cyclization is achieved